The aim of this study was to evaluate the effectiveness of autologous stem cell transplantation for patients with relapsed or primary chemotherapy-refractory myeloma. Seventy-five patients, 50 men and 25 women, ages 33-68 years (median, 53 years), who underwent transplantation for relapsed or primary refractory myeloma were studied. Patients underwent transplantation 5-88 months (median, 23 months) after diagnosis of myeloma. The time to transplantation was significantly shorter in patients with refractory disease than for those with relapsed myeloma (median, 8 and 32 months, respectively; P Ͻ 0.001). Patients with primary refractory myeloma had a significantly lower plasma cell labeling index than those with relapsed disease (P ‫؍‬ 0.008). There were no differences in overall and complete response rates between patients with primary refractory and relapsed disease. The median survival of the entire cohort from diagnosis was 53 months. Overall survival from transplantation among patients with relapsed myeloma receiving therapy, relapsed myeloma off therapy, and primary refractory myeloma was significantly different (P ‫؍‬ 0.04), with median times of 12, 21 and 30 months, respectively. Progression-free survival also was different (P Ͻ 0.001), with median times of 7, 13, and 26 months, respectively. We conclude that overall and progression-free survival in patients with primary refractory myeloma appear better than in patients with relapsed disease and need further study.
in an attempt to improve response rate and survival. [5] [6] [7] A French randomized trial in previously untreated patients with myeloma confirmed improved survival with autologous marrow transplantation compared with conventional chemotherapy. 8 Many centers offer early transplantation to patients with newly diagnosed myeloma or to patients with stable (plateau phase) disease. However, it is possible to delay transplantation until relapse, provided stem cells are harvested and cryopreserved early in the disease course. Preliminary data from randomized trials comparing early vs delayed transplantation indicate that there is no significant difference in outcome between the two strategies. 9, 10 Patients with relapsed myeloma can be separated into two categories: those who relapse while receiving conventional chemotherapy and those who relapse after stopping such treatment. Both groups of patients are considered candidates for transplantation as soon as relapse occurs. Patients with primary chemotherapy-refractory myeloma represent a distinct group. Although these patients may not be considered good candidates for transplantation, they often undergo such treatment early in the disease course owing to a lack of other alternatives.
It is not clear how results of transplantation among patients who have relapsed disease compare with those obtained in patients who have primary chemotherapyrefractory myeloma. Here we describe our results with stem cell transplantation for three groups of patients with myeloma: primary chemotherapy-refractory disease (defined as disease progression or failure to achieve a 50% or greater reduction in monoclonal protein level with the initial standard-dose chemotherapy regimen), relapse while receiving conventional therapy, and relapse while off therapy.
Patients and methods
Seventy-five patients underwent high-dose therapy and blood cell transplantation for refractory or relapsed myeloma at the Mayo Clinic between June 1989 and February 1998. Data from transplant patients are collected prospectively and entered into a comprehensive computerized database. Information regarding response to therapy, relapse, and survival data is continuously updated.
No patients were lost to follow-up. All patients gave written informed consent for research bone marrow and blood samples and again before stem cell mobilization.
Approval of the Mayo Foundation Institutional Review
Board was obtained in accordance with federal regulations and the Declaration of Helsinki.
Stem cells were harvested from most patients after initial chemotherapy with vincristine, doxorubicin, and dexamethasone (VAD) chemotherapy. The conditioning regimen (high-dose therapy) consisted of melphalan (140 mg/m 2 ) and TBI (12 Gy total dose, administered over 3-4 days in twice-daily fractions) in 57 patients. Eleven patients received melphalan (140 mg/m 2 ), cyclophosphamide (120 mg/kg), and TBI (9 Gy total dose, administered over 3 days in twice-daily fractions) and three received melphalan (200 mg/m 2 ) alone. Four patients received other regimens. All patients had stem cells reinfused after high-dose therapy, except for one patient (included in the analysis) who died of sepsis 1 day before stem cell infusion.
Complete response was defined as lack of detectable monoclonal (M) protein in serum and urine by immunoelectrophoresis and immunofixation. Because a bone marrow biopsy was not performed routinely to document complete response, bone marrow plasma cells by light chain restriction were not included in the definition. Objective response was defined as reduction of serum M protein and 24-h urinary light chain excretion by at least 50% accompanied by a similar reduction of soft-tissue plasmacytomas if present. Patients with urine light chain only required a reduction of urinary light chain excretion to 10% or less of the pretreatment value.
Relapse (or progression in the case of partial responders) was defined as a 50% increase in the serum M protein or 24-h urinary M protein excretion over the lowest remission level. In patients achieving a complete response, any detectable M protein by immunofixation, even if nonmeasurable, constituted relapse. Increase in the size of existing lytic bony lesions or soft-tissue plasmacytomas or appearance of new lytic bony lesions constituted relapse (or progression), even if not accompanied by changes in the M protein.
Relapse had to be documented at least twice, separated by at least 2 weeks.
Overall survival was measured from the date of transplantation and from the date myeloma was initially diagnosed to the date of death or last follow-up. Progressionfree survival (PFS) was defined as time from transplantation to relapse, disease progression, or death.
Bone marrow plasma cell labeling index (PCLI), cytogenetics, and other laboratory variables were assessed pretransplantation. PCLI, a reflection of the proliferative activity, was determined using a slide-based immunofluorescence method on bone marrow samples, as described elsewhere. 11, 12 A PCLI у 1% was classified as high. For cytogenetic analysis, bone marrow specimens were processed by both direct and short-term culture techniques, as described previously.
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The 2 and Fisher exact tests were used to compare differences among the three subgroups for nominal variables; the rank-sum test was used for continuous variables. Survival analysis was done using the method described by Kaplan and Meier. 15 Differences between survival curves were tested for statistical significance using the two-tailed log-rank test and using the Cox proportional-hazards model. 16 Median survival times were estimated using the Weibull method.
17,18

Results
Fifty men and 25 women, ages 33-68 years (median, 53 years), were studied. All patients had received prior chemotherapy, and 87% had received two or more regimens. Sixty-three patients received transplants for relapsed disease: 30 had relapsed while off chemotherapy and 33 while still receiving standard-dose chemotherapy.
Twelve patients underwent transplantation for primary chemotherapy-refractory myeloma. Ten of these 12 patients were refractory to infusional VAD, including six patients who failed to respond to alkylator-based chemotherapy as well. The remaining two patients failed other multiagent combination chemotherapy regimens. Seven of the 12 patients had evidence of disease progression while receiving initial chemotherapy, and five underwent transplantation after failing to show evidence of objective response following three to four cycles of chemotherapy.
Patients underwent transplantation 5-88 months (median, 23 months) after the initial diagnosis of myeloma. The time to transplantation was significantly shorter in patients with refractory disease than in those with relapsed myeloma, with median times of 8 and 32 months, respectively (P Ͻ 0.001).
Baseline features
Patient characteristics are listed in Table 1 . The serum M protein was IgG in 54%, IgA in 21%, IgD in 3%, and light chain only in 22%. Kappa-to-lambda ratio was 2:1. There were no significant differences in heavy or light chain types among the three groups studied. The serum M protein spike ranged from 0.0 to 103 g/l (median, 19 g/l) at transplantation.
Thirty of 70 patients (43%) had abnormal marrow cytogenetics and most abnormalities (93%) were complex (у3 abnormalities). The serum lactate dehydrogenase value was Ͼ200 U/l in 21% of patients, and the C-reactive protein concentration was increased in 40%. There were no significant differences among the three groups in baseline characteristics, except for PCLI. More patients with primary refractory myeloma had a low PCLI (Ͻ1%) compared with those with relapsed disease (P ϭ 0.04). The median PCLI in patients with relapsed disease was 1.0% vs 0.1% in patients with primary refractory myeloma (P ϭ 0.008).
Response to transplantation
The overall response rate after high-dose therapy and transplantation was 90%. Complete response occurred in 32% of patients. Overall and complete response rates were not significantly different among the three groups (Table 2) .
Toxicity
The median duration of hospitalization was 17 days (range, 6-85 days). The incidence of prolonged hospitalization (Ͼ30 days) was 9% (seven patients). Delayed (Ͼ100 days) platelet or neutrophil engraftment occurred in five and two patients, respectively. Nonhematologic toxicity mainly consisted of mucositis, infection, diarrhea, nausea, and vomiting. Eighty-nine percent of patients had some degree of mucositis and, in 27 patients (36%), it was of grade 3-4 severity. Culture-proven bacteremia occurred in 40 patients (53%) and the most common organisms were gram-positive bacteria such as Staphylococcus aureus, coagulase-negative staphylococci, and Streptococcus viridans and Escherichia coli. Six patients with diarrhea had a stool volume Ͼ2 l/day. Other toxicities included noncardiogenic pulmonary edema (five patients), veno-occlusive disease (two patients) and intracranial hemorrhage (two patients).
Survival analysis
Forty-five patients died. Recurrent myeloma was the cause of death in 35 patients. Seven patients died of transplantrelated complications and one each from intracranial bleed, acute myeloid leukemia and suicide. Most transplantrelated deaths occurred during the early years of our transplant program. The median survival from the time myeloma was first diagnosed was 53 months. Median survival from the date of transplantation was 18 months for the cohort; PFS was 9 months. Overall survival from the time of transplantation among patients with relapsed myeloma receiving therapy, relapsed myeloma off therapy, and primary refractory myeloma was significantly different (P ϭ 0.04), with median times of 12, 21 and 30 months, respectively ( Figure 1a , Table 2 ). PFS was also different (P Ͻ 0.001), with median times of 7, 13 and 26 months, respectively (Figure 1b) . On further analysis, the differences were significant between primary refractory myeloma and relapse receiving therapy (P ϭ 0.04 for overall survival and Ͻ0.001 for PFS) and between relapse off therapy and relapse receiving therapy (P ϭ 0.04 for overall survival and P ϭ 0.007 for PFS). There were no significant differences in overall survival or PFS between primary refractory disease and relapse off therapy. There were also no significant differences among the three groups of patients in survival measured from the time myeloma initially was diagnosed (Figure 1c) .
Because there were significantly fewer patients with a high PCLI in the primary refractory group, the survival analysis was repeated after adjusting for PCLI using the Cox proportional-hazards model. The differences in overall survival among the three groups remained similar, but failed to achieve statistical significance owing to the small sample size. Differences in PFS continued to be significant (P ϭ 0.02). On multivariate analysis that included primary refractory myeloma, cytogenetics, labeling index, ␤ 2 -microglobulin, C-reactive protein, lactic dehydrogenase, and IgA M protein type as variables, primary refractory myeloma was not predictive of better survival. Abnormal cytogenetics (P ϭ 0.02) and ␤ 2 -microglobulin (P ϭ 0.04) were the only variables that predicted for overall survival in the multivariate model. Among patients with primary refractory myeloma, median survival after transplantation was 20 months among patients with progressive disease on standard chemotherapy vs 44 months in those with less than partial response to standard chemotherapy. Corresponding values for PFS were 17 and 38 months, respectively. Response to transplantation was similar, 86% and 80%, respectively. Owing to the small sample size, none of the above differences were statistically significant.
In patients with primary refractory disease, the PFS before transplantation was 6 months compared with 41 months after transplantation.
Discussion
Autologous stem cell transplantation is a treatment option for patients with primary chemotherapy-refractory disease and for those with relapsed myeloma. 5, 19 It is important to determine the differences in outcome with transplantation among the various subgroups of patients with poor-risk myeloma. 20 Primary chemotherapy-refractory patients may in general be thought to be poor candidates for transplantation. 21, 22 In other B cell malignancies such as non-Hodgkin's lymphoma, patients who are refractory to chemotherapy do poorly with transplantation. 23, 24 However, a clear doseresponse relationship is present in myeloma, and patients who fail to respond to standard chemotherapy such as VAD can be expected to respond well to myeloablative regimens. 19, 22, 25 We did not observe any significant differences in response rate between patients with relapsed and refractory myeloma. In fact, overall survival and PFS measured from the time of transplantation were superior in patients with refractory myeloma compared with those who had relapsed disease on therapy. Others described primary refractory disease as a favorable prognostic factor among patients undergoing transplantation for advanced myeloma. 19 One caveat is that this finding may be a result of lead-time bias because patients with primary refractory myeloma were transplanted sooner than patients with relapsed disease. Overall survival from the time of initial diagnosis ( Figure 1c ) may support this possibility. Primary refractory myeloma was not predictive of better survival on multivariate analysis.
Patients with primary refractory myeloma would have done poorly without transplantation. The time to progression before transplantation using aggressive chemotherapy was only 6 months in this group compared with 41 months after transplantation. Alexanian et al 21 retrospectively studied 41 patients with primary refractory myeloma treated with transplantation and found improved survival with such treatment compared with a control group of 61 patients treated with other standard-dose salvage chemotherapy, confirming this hypothesis.
There may be several reasons why patients with chemotherapy-refractory myeloma respond well to high-dose therapy and transplantation. These patients had significantly lower PCLIs compared with patients with relapsed myeloma, thereby contributing to a more favorable outcome. This finding is intriguing because the low PCLI, which is a reflection of low proliferative activity, may explain the refractoriness to chemotherapy in these patients. Cytogenetic abnormalities are a known adverse prognostic factor after transplantation for myeloma. 26, 27 We have recently shown that there is an excellent correlation between PCLI and cytogenetic abnormalities: a high PCLI is associated with a greater likelihood of abnormal cytogenetics. 27 Patients with refractory myeloma tended to have fewer cytogenetic abnormalities in our study. Less than 12 months of prior therapy is a favorable prognostic factor. The superior outcome with transplantation in primary refractory myeloma may also be an indication that some malignant clones need a much higher dose of chemotherapy for response. Compared with the high doses used in transplantation, doses used in standard therapy are insufficient in these cases. A short duration of prior chemotherapy also is less likely to induce the multidrug resistance gene, MDR1. 28 In our study, patients with primary refractory myeloma had a significantly shorter duration of chemotherapy before transplantation compared with patients who had relapsed myeloma (8 vs 32 months).
Patients with myeloma which relapses on therapy behave differently from those who relapse off therapy. Relapse while receiving therapy indicates chemotherapy refractoriness that develops during treatment and represents an unfavorable prognostic factor. In one study, the response rate with multiagent salvage chemotherapy was 92% for those with relapse off therapy compared with 34% for patients who relapsed while receiving therapy. 29 In our study, patients who relapsed while receiving therapy have the worst outcome among the groups studied. When such patients have other adverse prognostic features such as a high PCLI, abnormal cytogenetics, prolonged prior treatment, or high ␤ 2 -microglobulin concentration, outcome with autologous transplantation is dismal. 19, 26, 27 These patients are candidates for clinical trials studying more effective conditioning regimens, allogenic bone marrow transplantation, and other innovative post-transplantation treatment approaches.
Overall and complete response rates in this study are similar to those reported by others. 8, 19, 30, 31 Survival after transplantation in our study (median, 18 months) appears lower than that reported by others. 4, 26, 31 This is clearly the result of patient selection because we only studied patients with relapsed or refractory myeloma. Survival after transplantation in our study is similar to a cohort of patients with advanced myeloma studied by Alexanian and colleagues. 32 Median survival measured from initial diagnosis of myeloma in the patients we studied was 53 months and is similar to results reported by other investigators. 9 Owing to relatively small sample size, many of the known prognostic factors were not predictive of survival in a multivariate analysis. Infection, mucositis, and diarrhea were the major toxic reactions. Nausea and vomiting are readily controlled with the routine use of ondansetron or granisetron. Overall, toxicity was comparable to that observed by other investigators. [5] [6] [7] [8] In summary, transplantation offers effective palliation for patients with relapsed and refractory myeloma. The outcome may be better for patients with primary chemotherapy-refractory myeloma, and such patients should probably not be excluded from transplant considerations. However, this observation needs further confirmatory studies. Results are not satisfactory for patients who relapse while receiving therapy. Other innovative strategies are needed to improve the success of high-dose therapy in highrisk myeloma.
